Latest News and Press Releases

REDWOOD CITY, Calif., March 11, 2025 (GLOBE NEWSWIRE) -- AmMax Bio, Inc. (“AmMax”), a private clinical-stage biopharmaceutical company developing innovative therapeutics in oncology, today announced...

AMB-066 is a potential first-in-class treatment for CRC MRD ~20,000 patients diagnosed annually in U.S.; no currently approved therapies     REDWOOD CITY, Calif., Jan. 27, 2025 (GLOBE NEWSWIRE)...

AmMax Bio and MD Anderson to Advance Development of AMB-066 in Colorectal Cancer Patients with Minimal Residual Disease

REDWOOD CITY, Calif., Sept. 27, 2024 (GLOBE NEWSWIRE) -- AmMax Bio, Inc., a private clinical-stage biopharmaceutical company developing innovative therapeutics in oncology, today announced that it...

Study designed to optimize treatment regimen and evaluate efficacy over six-month dosing period Initial results expected in second half of 2023 REDWOOD CITY, Calif., Jan. 30, 2023 (GLOBE NEWSWIRE)...

AMB-05X is the First and Only Investigational Drug Candidate to Receive PRIME Designation for the Treatment of TGCT PRIME Designation Validates Unique Therapeutic Potential of AMB-05X as Demonstrated...

This novel ADC is expected to have a wider therapeutic index and superior clinical profile across a broad range of solid tumors     IND submission is planned for mid-2023 REDWOOD CITY, Calif. and...

Using local administration for a local disease, positive clinical results suggest AMB-05X could become best-in-class treatment for the diverse population of TGCT patients Positive Proof-of-Concept...

New Patents Issued and Fast Track Designation Support Development of the Only Locally-Administered Drug Treatment for TGCT Positive Proof-of-Concept Results Lead to Extension of Phase 2 Study to...

REDWOOD CITY, Calif., Sept. 12, 2022 (GLOBE NEWSWIRE) -- AmMax Bio, Inc. (“AmMax”), a private clinical-stage biopharmaceutical company developing innovative therapeutics in oncology, including...